Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 23, 2026 1 hour, 41 minutes ago
Medical News: A new laboratory study is raising fresh hope in the fight against ovarian cancer, one of the deadliest cancers affecting women worldwide. Researchers have discovered that combining a common diabetes drug with two naturally occurring compounds may significantly slow down cancer cell growth and spread, offering a potential new direction for future treatments.
A novel three-compound combination dramatically slows ovarian cancer cell growth and spread in early lab studies
A Powerful Three-Part Combination
Scientists from Istanbul Atlas University—including the Department of Histology and Embryology, the Department of Obstetrics and Gynecology, and the Department of Biochemistry—investigated how metformin, boric acid, and resveratrol work together against ovarian cancer cells. Their focus was on a well-known cancer cell model called SKOV3, often used to study aggressive ovarian tumors.
Metformin is widely prescribed for type 2 diabetes, but it has increasingly drawn attention for its anti-cancer potential. Boric acid is a naturally occurring compound linked to anti-inflammatory and antioxidant effects, while resveratrol is a plant-based substance found in grapes and berries, known for its health-promoting properties.
When tested individually, each of these substances reduced cancer cell survival to some extent. However, the real breakthrough came when they were combined. The study showed that pairing metformin with either boric acid or resveratrol resulted in much stronger anti-cancer effects than using any single agent alone.
Slowing Cancer Growth and Spread
The researchers found that the combination treatments significantly reduced the ability of ovarian cancer cells to grow and multiply. More importantly, they also slowed down the movement of these cells, which is critical because cancer spread, or metastasis, is a major cause of death in ovarian cancer patients.
In some cases, the combination treatments reduced cell migration by more than 90 percent over a 72-hour period. This suggests that the therapy could potentially help prevent tumors from spreading to other parts of the body.
Targeting Inflammation and Tumor Signals
Another key finding was the impact on inflammation-related molecules that help cancer thrive. The treatments reduced levels of IL-17 and NF-kB, both of which are known to promote tumor growth and survival. At the same time, levels of a protein called midkine, often linked to cancer progression and resistance to treatment, were also lowered.
By disrupting these signals, the combination therapy appears to attack cancer on multiple fronts, not just by killing cells but also by weakening the environment that allows tumors to grow.
Triggering Cancer Cell Shutdown
The study also showed an increase in a protein called p21, which plays a crucial role in stopping cells from dividing. Higher levels of p21 indicate that cancer cells are being pushed into a state where they can no longer grow or replicate effectively.
This multi-layered approach&mdas
h;reducing growth, limiting spread, lowering inflammation, and halting cell division—makes the findings particularly promising.
Important Limitations and Next Steps
Despite the encouraging results, the research is still in its early stages. The experiments were conducted only in laboratory-grown cancer cells, and the safety of this combination in healthy cells has not yet been tested. Additionally, some of the drug concentrations used in the study may not directly reflect what is achievable in real patients.
More research, including animal studies and clinical trials, will be needed before this approach can be considered for real-world treatment.
Conclusion
The findings of this
Medical News report highlight a potentially powerful new strategy for tackling ovarian cancer using a combination of metformin, boric acid, and resveratrol. By simultaneously targeting cancer cell growth, migration, inflammation, and cell cycle regulation, this triple therapy approach could pave the way for more effective and less toxic treatments in the future. However, extensive further research is essential to confirm safety, determine optimal dosing, and evaluate real clinical benefits before it can be adopted in medical practice.
The study findings were published in the peer reviewed journal: Biomedicines.
https://www.mdpi.com/2227-9059/14/3/719
For the latest cancer research, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/cancer
Share
Tweet
Share
